Proto Script Pharmaceutical Corp. (PSCR) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
9830 6TH STREET, SUITE 103 RANCHO CUCAMONGA, CA 91730 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 733 - Mailing, Reproduction, Commercial Art And Photography, and Stenographic Services (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2017 MRQ | 12/31/2016 | 5/31/2016 | 5/31/2015 | 5/31/2014 | 5/31/2013 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 4 | 12 | 1 | 14 | 46 | |||
| Cash and cash equivalent | 4 | 12 | 1 | 14 | 46 | |||
| Receivables | 140 | |||||||
| Other current assets | 1 | ✕ | ||||||
| Other undisclosed current assets | 1 | |||||||
| Total current assets: | 145 | 12 | 1 | 14 | 47 | |||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 26 | |||||||
| Total noncurrent assets: | 26 | |||||||
| TOTAL ASSETS: | 170 | 12 | 1 | 14 | 47 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 179 | 7 | 12 | 12 | 8 | |||
| Employee-related liabilities | 21 | |||||||
| Accounts payable | 157 | 9 | 3 | |||||
| Accrued liabilities | 4 | 5 | ||||||
| Other undisclosed accounts payable and accrued liabilities | 7 | 12 | ||||||
| Debt | 51 | |||||||
| Other liabilities | 167 | |||||||
| Due to related parties | 17 | 82 | 33 | |||||
| Other undisclosed current liabilities | 75 | |||||||
| Total current liabilities: | 490 | 89 | 45 | 12 | 8 | |||
| Noncurrent Liabilities | ||||||||
| Total liabilities: | 490 | 89 | 45 | 12 | 8 | |||
| Equity | ||||||||
| Equity, attributable to parent, including: | (320) | (77) | (44) | 1 | 40 | |||
| Common stock | 344 | 3 | 3 | 3 | 3 | |||
| Additional paid in capital | 6,953 | 106 | 106 | 106 | 106 | |||
| Accumulated deficit | (7,617) | (186) | (153) | (108) | ||||
| Other undisclosed equity, attributable to parent | (70) | |||||||
| Total equity: | (320) | (77) | (44) | 1 | 40 | |||
| TOTAL LIABILITIES AND EQUITY: | 170 | 12 | 1 | 14 | 47 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2017 TTM | 12/31/2016 | 5/31/2016 | 5/31/2015 | 5/31/2014 | 5/31/2013 | ||
|---|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 789 | ||||||
| Cost of revenue (Cost of Product and Service Sold) | (224) | (9) | (5) | ||||
| Gross profit: | 564 | (9) | (5) | ||||
| Operating expenses | (863) | (33) | (45) | (38) | (46) | ||
| Other undisclosed operating income | 14 | ||||||
| Operating loss: | (298) | (42) | (50) | (38) | (32) | ||
| Nonoperating expense | (6,885) | ||||||
| Interest and debt expense | (6,885) | ||||||
| Loss from continuing operations: | (14,067) | (42) | (50) | (38) | (32) | ||
| Loss before gain (loss) on sale of properties: | (14,067) | (42) | (50) | (38) | (32) | ||
| Net loss: | (14,067) | (42) | (50) | (38) | (32) | ||
| Other undisclosed net income attributable to parent | 6,885 | 9 | 5 | ||||
| Net loss available to common stockholders, diluted: | (7,183) | (33) | (45) | (38) | (32) | ||
Comprehensive Income ($ in thousands)
| 9/30/2017 TTM | 12/31/2016 | 5/31/2016 | 5/31/2015 | 5/31/2014 | 5/31/2013 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (14,067) | (42) | (50) | (38) | (32) | ||
| Comprehensive loss, net of tax, attributable to parent: | (14,067) | (42) | (50) | (38) | (32) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.